Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to treat ...

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), scooping up 145,153 shares in the gene-editing play. For the most part, it ...

Wave Life Sciences Ltd. (NASDAQ:WVE) tops our list for being one of the most promising stocks. TheFly reported on December 16 that Oppenheimer raised its price target on WVE to $32 from $24 while ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary -- The ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...